Corbus Pharmaceuticals Share Price Today

Mizuho cuts Corbus Pharmaceuticals PT to $23, maintains Outperform

Mizuho lowered Corbus Pharmaceuticals' price target from $24 to $23. Analyst Graig Suvannavejh maintained an Outperform rating on the stock. RBC and Wedbush also recently cut targets to $33 and $27 respectively. All three brokers retain Outperform ratings despite valuation adjustments.

HC Wainwright reiterates Buy on Corbus Pharma, keeps $35 target

HC Wainwright & Co. reiterates Buy rating on Corbus Pharmaceuticals. Price target maintained at $35 per share. Analyst Andres Y. Maldonado issued the update.

Corbus CRB-913 shows 5% weight loss in obesity trial, avoids depressive effects

CRB-913 achieved 5% mean weight loss at 60mg dose in 12-week Phase 1b trial. Drug showed fewer GI adverse events than oral GLP-1s and avoided depressive side effects. Discontinuation rates ranged from 3.1% to 13.1%, lower than discontinued monlunabant. Zero cases of suicidality observed among 188 participants; irritability was most common psychiatric effect. Corbus plans FDA consultation for Phase 2 monotherapy trial in first half of 2027.

Corbus grants equity awards to new CMO Leonardo Nicacio

Corbus Pharmaceuticals appointed Leonardo Nicacio as Chief Medical Officer and granted him inducement equity awards comprising 191,676 stock options and 58,333 RSUs. The Compensation Committee approved the grants effective August 16, 2026, under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $10.09 and vest over four years, while the RSUs vest annually over four years.

Corbus Pharmaceuticals signs $127.5M stock sale deal with Jefferies

Corbus Pharmaceuticals has secured an agreement with Jefferies to sell up to $127.5 million in common stock via an at-the-market offering. This flexible financing tool allows the company to raise capital gradually through open market sales, providing liquidity for general corporate purposes while mitigating the market impact associated with larger, fixed-price equity raises.

Corbus completes CANYON-1 Phase 1b trial for obesity drug CRB-913

Corbus Pharmaceuticals Holdings, Inc. announced the completion of the last patient last visit in its CANYON-1 Phase 1b clinical trial for CRB-913, an oral CB1 inverse agonist for obesity. The study enrolled 240 participants across three dose cohorts and one placebo group in the United States. Topline data is scheduled for release in September 2026. The drug aims to provide an orthogonal treatment option beyond GLP-1 therapies, addressing high discontinuation rates in current treatments. Early Phase 1a data showed promising weight loss and a favorable safety profile with low brain penetration compared to previous CB1 agonists.